Doseloop Beta

Fosphenytoin

medication Under review

A prodrug of phenytoin used as an anticonvulsant for the control of generalized tonic-clonic status epilepticus.

Research summary

AI-Generated Content: This summary was created by AI and may contain errors. Always verify with peer-reviewed sources.

In healthy human subjects, fosphenytoin has not been studied as a supplement for performance, cognition, or wellness. The available human evidence is almost entirely from clinical use in patients with seizures or perioperative settings, where it shows expected antiseizure pharmacology and a safety profile shaped by conversion to phenytoin. Across labeling and comparative clinical studies, common adverse effects include pruritus, dizziness, headache, fatigue, tremor, hypotension, nystagmus, ataxia, vomiting, and rash. Because the evidence base is disease-treatment focused rather than healthy-volunteer focused, there is no credible healthy-subject evidence for any supplement-like benefit.

Reported Side Effects

Related health conditions

Research showing how this habit affects specific health conditions. Always consult healthcare professionals.

May Help With

Research (4 studies)

Preliminary

Highlights of Prescribing Information: CEREBYX

Drug label • 2026

Pfizer

Preliminary

Fosphenytoin - StatPearls

NCBI Bookshelf • 2024

StatPearls authors

RCT

Comparison of pharmacokinetics and safety between a new phosphonooxymethyl prodrug of phenytoin and two fosphenytoin sodium products in healthy volunteers

Frontiers in Pharmacology • 2023

Wang et al.

Preliminary

CEREBYX (fosphenytoin sodium injection) Prescribing Information

Drug label • 2007

Pfizer

Community updates

No updates yet for this supplement.

Be the first to share your experience!

At a glance

Users tracking 0
Linked studies 4
Researched benefits 0
Side effects noted 6